Novartis Unveils Promising Phase II Data For Meningitis B Vaccine
This article was originally published in The Pink Sheet Daily
Executive Summary
Data show dosing series produces protective immune response in infants.
You may also be interested in...
Novartis Needs A Bigger Safety Database For Menveo, FDA Says
Review of application for ages 11 and up proceeds, but the agency wants to see more data on infants, pushing a second filing for the meningitis vaccine to 2011 in the U.S.
Novartis Needs A Bigger Safety Database For Menveo, FDA Says
Review of application for ages 11 and up proceeds, but the agency wants to see more data on infants, pushing a second filing for the meningitis vaccine to 2011 in the U.S.
Novartis Vaccines Unit Makes Move Into Crowded CMV Competition
Licensing deal for AlphaVax’s Phase I CMV candidate also includes options for RSV vaccine candidate and 4 million share stock purchase.